Working… Menu

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03509545
Recruitment Status : Not yet recruiting
First Posted : April 26, 2018
Last Update Posted : April 26, 2018
Information provided by (Responsible Party):
Sarfez Pharmaceuticals, Inc.

Brief Summary:
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Condition or disease Intervention/treatment Phase
Body Weight Changes Drug: CHF Patients: ER Torsemide 40 mg Drug: CHF Patients: Furosemide 40 mg Phase 1

Detailed Description:
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide
Estimated Study Start Date : July 17, 2018
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: CHF Patients: ER Torsemide 40 mg
CHF patients will be given 40 mg ER Torsemide
Drug: CHF Patients: ER Torsemide 40 mg
ER Torsemide 40mg given once daily to CHF patients
Other Name: Demadex

Active Comparator: CHF Patients: Furosemide 40 mg
CHF patients are on 40 mg of Furosemide
Drug: CHF Patients: Furosemide 40 mg
Stable CHF patients taking twice-daily 40 mg Furosemide
Other Name: Lasix

Primary Outcome Measures :
  1. change in 24-hour sodium excretion compared to baseline [ Time Frame: 24 hours ]
    the difference in 24 hour sodium excretion between ER Torsemide and Furosemide

Secondary Outcome Measures :
  1. Changes in body weight [ Time Frame: 2 weeks ]
    Body weight changes will be compared between the two arms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion Criteria:

  • Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03509545

Layout table for location contacts
Contact: Jaya Patel, MS +91 8028082838

Layout table for location information
Syngene International Completed
Bangalore, Karnataka, India, 560099
Sponsors and Collaborators
Sarfez Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Anil K, MD Syngene International

Layout table for additonal information
Responsible Party: Sarfez Pharmaceuticals, Inc. Identifier: NCT03509545     History of Changes
Other Study ID Numbers: CLCD-075-17
First Posted: April 26, 2018    Key Record Dates
Last Update Posted: April 26, 2018
Last Verified: April 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Sarfez Pharmaceuticals, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Body Weight Changes
Signs and Symptoms
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents